Clinical study of umbilical cord blood infusion in the treatment of Juvenile myelomonocytic leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074626

Enrollment

Unknown

Registered

2023-08-10

Start date

2023-08-31

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile myelomonocytic leukemia

Interventions

Case series:A clinical study of chemotherapy combined with umbilical cord blood transfusion for the treatment of juvenile myelomonocytic leukemia

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old, weight =40 kg, both male and female; 2. Meet the WHO 2016 diagnostic criteria for juvenile myelomonocytic leukemia, including any of the following situations: (1) Patients in the medium-risk group did not achieve remission or disease progression after at least 2 courses of chemotherapy; (2) High-risk group children; 3. ECOG score = 2 points; 4. Informed consent of the legal guardian and voluntary participation; Subjects suitable for this study should meet the above four criteria at the same time.

Exclusion criteria

Exclusion criteria: 1. Age > 18 years old; 2. Have serious organ dysfunction or diseases, such as heart, liver, kidney, pancreas, and other serious diseases and dysfunction; 3. HIV positive, active hepatitis B / AIDS or active tuberculosis. 4. Suffering from other serious infections that are uncontrollable and may be life-threatening; 5. Suffering from other primary tumors; 6. Suffering from serious mental illness, which may interfere with the participation in this clinical study; 7. Hypersensitivity to blood products; 8. Previously received hematopoietic stem cell transplantation; 9. Any other circumstances recognized by the investigator that are not suitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Overall survival;Relapse-free survival;complete response rate;partial response rate;	—

Secondary

Measure	Time frame
Hematopoietic reconstitution time;Incidence of pre-engraftment syndrome;	—

Countries

China

Contacts

Public ContactLiu Fang

Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences

liufang@ihcams.ac.cn+86 135 0213 8050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026